The RubrYc platform lends itself to multi-modal partnerships to drive the development of biologics ranging from conventional monoclonal antibodies (mAbs) for specific novel epitopes, and epitope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback